Breast Cancer

, Volume 16, Issue 4, pp 295–300

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review

  • Yutaka Tokuda
  • Yasuhiro Suzuki
  • Yuki Saito
  • Shinobu Umemura
Special Feature New strategy for HER-2 testing and trastuzumab therapy

DOI: 10.1007/s12282-009-0142-8

Cite this article as:
Tokuda, Y., Suzuki, Y., Saito, Y. et al. Breast Cancer (2009) 16: 295. doi:10.1007/s12282-009-0142-8

Abstract

Currently, trastuzumab is one of the key drugs in the treatment strategy for HER2-positive breast cancer. Although metastatic breast cancer is unlikely to be cured, some HER2-positive patients have survived for a long time with complete response to trastuzumab therapy. In HER2-positive metastatic breast cancer, single agent trastuzumab is effective and less toxic. Combination of trastuzumab with cytotoxic drugs is also effective. Therefore, major guidelines recommend using trastuzumab as a key drug in the management of HER2-positive metastatic breast cancer. However, many clinical questions still need to be solved. In this article, recent evidence was reviewed to find some answers about these issues.

Keywords

Metastatic breast cancerHER2-positiveTrastuzumab

Copyright information

© The Japanese Breast Cancer Society 2009

Authors and Affiliations

  • Yutaka Tokuda
    • 1
  • Yasuhiro Suzuki
    • 1
  • Yuki Saito
    • 1
  • Shinobu Umemura
    • 2
  1. 1.Department of Breast and Endocrine SurgeryTokai University School of MedicineIseharaJapan
  2. 2.Department of PathologyTokai University School of MedicineIseharaJapan